The 3-year survival rate of patients with advanced-stage, ALK-positive AD who received first line ALK-TKI was 73.0% (95% CI, 63.0%-84.6%) in period I. It was 76.9% (95% CI, 70.3%-84.1%) in period II (P = .55). This evidence concerns the gene ALK and Alzheimer disease.